Toxic epidermal necrolysis [Lyell]
ICD-10 L51.2 is a billable code used to indicate a diagnosis of toxic epidermal necrolysis [lyell].
Toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, is a severe skin condition characterized by widespread detachment of the epidermis from the dermis, leading to extensive skin loss and vulnerability to infections. Clinically, it presents with flu-like symptoms, followed by the rapid onset of erythematous macules and blisters that coalesce to form large areas of denuded skin. The condition can affect mucosal surfaces, including the eyes, mouth, and genitals, leading to significant morbidity. The underlying pathophysiology often involves a hypersensitivity reaction to medications, infections, or other triggers. Disease progression can be rapid, with potential complications such as sepsis, fluid loss, and electrolyte imbalances. Diagnosis is primarily clinical, supported by skin biopsy when necessary. Early recognition and intervention are crucial for improving outcomes, as mortality rates can be high without prompt treatment. Management typically involves hospitalization, supportive care, and addressing the underlying cause, often necessitating the use of immunosuppressive therapies.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L51.2 specifically covers toxic epidermal necrolysis, which is primarily triggered by adverse drug reactions, but may also be associated with infections or other factors. Diagnostic criteria include the presence of extensive skin detachment and systemic symptoms.
L51.2 should be used when a patient presents with the classic symptoms of toxic epidermal necrolysis, particularly when there is significant skin detachment and systemic involvement, distinguishing it from less severe conditions like Stevens-Johnson syndrome.
Documentation should include a detailed clinical history, description of skin findings, any precipitating factors such as recent medication use, and evidence of systemic involvement. Photographic documentation may also be beneficial.
